lock Open Access lock Peer-Reviewed




COVID-19 and Methylene Blue

Viroj WiwanitkitI

DOI: 10.21470/1678-9741-2020-0462

Dear Editor, I would like to comment on the article "COVID-19 should be a methylene blue "promoter"[1]". Evora noted that "I decided to resubmit the letter now, considering that COVID-19 should be a methylene blue 'promoter', and the dye can get the lifesaving status it deserves [1]." In fact, the use of classic available agent as a possible therapeutic agent for the emerging COVID-19 should be supported. It is better than do nothing. Many classic drugs such as hydroxychloroquine are proposed and tested for managing COVID-19[2]. At the moment, we have to take the risk of a new alternative proposal for the treatment of COVID-19 such as convalescent plasma therapy[3]. Using a safe and well-known agent might not have a confirmation for its efficacy but we have many data on its safety, and it might be a good alternative option compared to a totally unknown new alternative.


1. Evora PRB. COVID-19 should be a methylene blue "promoter". Braz JCardiovasc Surg. 2020;35(4):604-5.doi:10.21470/1678-9741-1-2020-0607. [MedLine]

2. Joob B, Wiwanitkit V. Evidence of protective effect ofhydroxychloroquine on COVID-19. J Rheumatol. 2020;47(10):1587.doi:10.3899/jrheum.200638.

3. Wiwanitkit V. Convalescent plasma therapy in the treatment ofCOVID-19: some considerations: correspondence. Int J Surg. 2020;80:26.doi:10.1016/j.ijsu.2020.06.029.

CCBY All scientific articles published at are licensed under a Creative Commons license


All rights reserved 2017 / © 2024 Brazilian Society of Cardiovascular Surgery DEVELOPMENT BY